AMISORB DENTAL PRODUCT

Description
AMISORB is a new effective pharmaceutical composition based on a low molecular weight fibrinolysis inhibitor – ε-aminocaproic acid immobilized on homemade enterosorbents. The preparation has a prolonged antifibrinolitic effect and exhibits antimicrobial activity due to adsorption of dental pathogenic microflora, in particular, Staphylococcus aureus. Two to four applications eliminate gingival edema and hyperemia, reduce bleeding, and stop pyorrhea. The preparation is used as applications after appropriate treatment of parodontal pockets.

Technical appraisal and economic benefits
• prolonged action on afflicted parodontal tissues;
• a factor of two to three reduction in the dental recovery period;
• lengthening of the disease remission phase;
• ease of use in dental care;
• simple production process and availability of ingredients.
The product has no analogs among well-known application materials.

Application areas
Treatment of periodontal diseases: periodontitis and gingivitis.

Development stage
Clinical trials of AMISORB have been performed at dental departments of Moscow and Novosibirsk. The following technical documentation is available:
– formulation of AMISORB preparation;
– instruction for using in clinical practice approved by Novosibirsk Regional Health Department;
– trial reports.

Patent situation

Commercial Offers
Joint bringing of the product to a commercial level.
Sale of licenses.

Estimated cost
Price is to be negotiated.

Contacts
Dr.Sc. Valentina I. Simagina, Head of Coordination Laboratory
Boreskov Institute of Catalysis, Siberian Branch of the Russian Academy of Sciences
5, Prosp. Akademika Lavrentieva, Novosibirsk, 630090, Russia
Phone: (383) 330-73-36
Fax: (383) 330-80-56
E-mail: bic@catalysis.nsk.su
http://www.catalysis.nsk.su